Related references
Note: Only part of the references are listed.Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
T. Powles et al.
ANNALS OF ONCOLOGY (2022)
Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations
Vincent Lemaire et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases
Meng Qiao et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects
Shima Makaremi et al.
BIOMEDICINES (2021)
Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy
Ines Pires da Silva et al.
CANCER (2020)
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Raju K. Vaddepally et al.
CANCERS (2020)
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy
Andrea Botticelli et al.
VACCINES (2020)
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee
O. Michielin et al.
ANNALS OF ONCOLOGY (2020)
Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors
Denis Maillet et al.
EUROPEAN JOURNAL OF CANCER (2020)
Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
Mohamed A. Abd El Aziz et al.
VACCINES (2020)
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Escudier et al.
ANNALS OF ONCOLOGY (2019)
Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
Maddalena Centanni et al.
CLINICAL PHARMACOKINETICS (2019)
Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action
Ni Zhang et al.
IMMUNOTHERAPY (2019)
Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy
Mehmet Asim Bilen et al.
BMC CANCER (2019)
Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting
Pauline Corbaux et al.
EUROPEAN JOURNAL OF CANCER (2019)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer
Amanda Jane Williams Gibson et al.
MEDICAL ONCOLOGY (2018)
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun V. Balar et al.
LANCET ONCOLOGY (2017)
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
Paul C. Tumeh et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy
Adi Nosrati et al.
BRITISH JOURNAL OF CANCER (2017)
Role of the Microenvironment in Liver Metastasis: From Pre- to Prometastatic Niches
Pnina Brodt
CLINICAL CANCER RESEARCH (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Lymphocyte-to-monocyte ratio predicts survival after radiofrequency ablation for colorectal liver metastases
Antonio Facciorusso et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study
L. E. Hendriks et al.
EUROPEAN JOURNAL OF CANCER (2015)
Specific organ metastases and survival in metastatic non-small-cell lung cancer
Tomohiro Tamura et al.
MOLECULAR AND CLINICAL ONCOLOGY (2015)
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease
B. Besse et al.
ANNALS OF ONCOLOGY (2014)
Metastatic sites and survival in lung cancer
M. Riihimaeki et al.
LUNG CANCER (2014)
Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center
Ignacio Garrido-Laguna et al.
CANCER (2012)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer (vol 17, pg v118, 2006)
Hans von der Maase et al.
ANNALS OF ONCOLOGY (2011)
Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience
H-T Arkenau et al.
BRITISH JOURNAL OF CANCER (2008)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
H von der Maase et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Passive and active mechanisms trap activated CD8+ T cells in the liver
B John et al.
JOURNAL OF IMMUNOLOGY (2004)
Metastatic urothelial cancer: Evaluation of prognostic factors and change in prognosis during the last twenty years
L Sengelov et al.
EUROPEAN UROLOGY (2001)
Share Paper
